Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    How Water Collects on Flat Streets Near the Harbor

    November 20, 2026

    What it means for your traffic

    November 20, 2026

    How Often Do Bonds Beat Stocks?

    November 20, 2026
    Facebook X (Twitter) Instagram
    Trending
    • How Water Collects on Flat Streets Near the Harbor
    • What it means for your traffic
    • How Often Do Bonds Beat Stocks?
    • Why Black Friday and Cyber Monday Are Bad Days to Impulse Buy Electronics
    • You Don’t Need Cash to Buy a Competitor
    • Anthropic’s IPO could deliver $156 billion to charity
    • Sweden’s H100 Lines Up Bitcoin Trading Revenue for Share Buybacks – BitRss
    • Nurses Share The Worst Mistakes They’ve Ever Seen
    Facebook X (Twitter)
    SBM Global News
    Demo
    • Home
    • Top Stories
      • Politics
    • Business
      • Small Business
      • Marketing
    • Finance
      • Investment
    • Technology

      Anthropic’s IPO could deliver $156 billion to charity

      November 20, 2026
      Read More

      Biz4Group LLC – Company Profile

      November 19, 2026
      Read More

      Nvidia’s startup stakes ballooned to $65B, but Huang’s exit puts future deals in doubt

      November 18, 2026
      Read More

      Authenticom, Inc. – Company Profile

      November 17, 2026
      Read More

      Island is a new screen-time app that turns staying off your phone into a game

      November 17, 2026
      Read More
    • Lifestyle
      • Travel
    • Feel Good
    • Get In Touch
    SBM Global News
    Demo
    Home»Investment»An overlooked corner of women’s health may be $350 billion market opportunity
    Investment

    An overlooked corner of women’s health may be $350 billion market opportunity

    By Staff WriterMarch 16, 20246 Mins Read
    Facebook Twitter LinkedIn Reddit Email
    #image_title
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Peathegee Inc | Tetra Images | Getty Images

    After years of being ignored, menopause has entered the public conversation.

    Celebrities from Drew Barrymore to Naomi Watts have opened up about symptoms and promoted products. Yet despite the increased chatter, there is a long way to go when it comes to treating symptoms — and a lot of opportunities for companies to step in to fill the gap.

    In fact, menopause is among the female health conditions with the highest unmet need and has “enormous potential for innovative treatments,” according to a recent McKinsey report.

    The management consultant estimates the global market potential to treat symptoms ranges from $120 billion to as much as $350 billion globally.

    Menopause occurs when women have gone 12 consecutive months without a menstrual period. While that happens, on average, at around age 51, women can have symptoms for years beforehand in what’s known as perimenopause. Symptoms can also continue in the postmenopausal phase.

    Those symptoms include hot flashes, anxiety, weight gain, vaginal dryness, mood changes, sleep problems and changes in skin conditions. More than 450 million women worldwide are affected by menopause and perimenopause symptoms, according to McKinsey.

    There is also a big unmet demand for menopause products and services, said Anna Pione, a partner at McKinsey who leads the firm’s research on the future of wellness.

    Menopause is “underserved, underfunded, underpaid attention to,” she said. “That would apply to women’s health in general, and then specifically and acutely to menopause in particular.”

    ‘Exciting’ developments

    Hormone therapy was the typical menopause treatment for decades. However, it got a bad rap in 2002 after a Women’s Health Initiative study found estrogen plus progestin therapy increased a woman’s risk of breast cancer and heart disease.

    “A lot of women bailed off hormone therapy for their own fear, or because their doctors were afraid, or some combination thereof,” said Dr. Stephanie Faubion, director of the Mayo Clinic Center for Women’s Health and medical director of the nonprofit Menopause Society.

    From 2002 to 2009, hormone therapy claims were reduced by more than 70%, a 2012 study showed.

    “It left a lot of women without any management at all,” Faubion said.

    Demo

    However, research now shows that the benefits may outweigh the risks for women under age 60, or less than 10 years out of their menopause diagnosis.

    “Our knowledge has changed,” said Dr. Karen Adams, a Stanford University professor and director of the school’s menopause and healthy aging program. “It is really very exciting, but women are left shaking the trees trying to find someone who can help them.”

    Investing in the theme

    There are not many publicly-listed companies in the space. The largest U.S. name is Pfizer, which has a number of products in its portfolio. They include Duavee and Premarin, hormone therapy treatments for hot flashes and the prevention of osteoporosis.

    Stock Chart IconStock chart icon

    hide content

    Pfizer year to date

    Then, there is tiny Biote, which has a market cap just north of $400 million. The company, which went public in May 2022 through a SPAC deal, makes customized bioidentical hormone pellets to address hormone imbalances.

    Hormone treatment in general is an area of focus that is “really bubbling up to the surface,” said Jefferies analyst Kaumil Gajrawala, who has a buy rating on Biote.

    Menopause is the largest part of its market, he said. Biote uses blood tests to customize its hormone pellets, which are inserted into the body subcutaneously.

    “It gives you that consistent amount of delivery, and … there’s no concern about compliance and if you’ll remember a day or forget a day,” he said. “What it means in the end is that you feel better.”

    Stock Chart IconStock chart icon

    hide content

    Biote year to date

    Meanwhile, Dare Bioscience, which has an even smaller market cap of about $47 million, has a hormone therapy in the pipeline. The clinical-stage biopharmaceutical company, which focuses on women’s health, has an intravaginal ring hormone therapy that is set to progress to a single Phase 3 study.

    There is also a race to find non-hormone treatments.

    Last May, the Food and Drug Administration approved Tokyo-based Astellas Pharma’s Veozah, also known as fezolinetant, to treat hot flashes.

    Bayer also has a drug in its pipeline called elinzanetant. The German company said in January that therapy reduced the frequency and severity of hot flashes and improved sleep in two late-stage trials. The results of a third phase 3 study is expected in coming months, Bayer said. It will then submit for approval.

    In addition, late-clinical-stage biopharmaceutical company Vistagen Therapeutics, with a market cap of about $100 million, has a trial underway for a hormone-free nasal spray to treat hot flashes.

    In the non-drug category, fertility benefits manager Progyny recently announced it was expanding into menopause coverage by partnering with private companies Gennev and Midi Health.

    “The fact that they are focusing on menopause as one of the next legs of the stool is an indicator of the potential opportunity there,” said Sasha Kelemen, the head of women’s health investment banking at Leerink Partners.

    Private innovation

    Still, much of the innovation in menopause is happening in the private space.

    “Menopause is inevitable, like death and taxes, and all women will go through this,” Kelemen said. “We just don’t have a lot of public women’s health companies yet, and hopefully that will change.”

    In 2022, Kelemen orchestrated a deal for Unified Women’s Healthcare to buy Gennev, the Progyny partner that’s a digital menopause care delivery platform. Kelemen would not disclose the financial terms.

    Midi Health, the other Progyny partner that’s a virtual care clinic specializing in perimenopause and menopause, is another company attracting investor dollars. In September, Alphabet‘s venture capital arm, Google Ventures, led a $25 million Series A funding round for the company, bringing its total funding to $40 million.

    Still, women’s health has long been underfunded, and menopause is getting just a small slice of that pie.

    “The dollars don’t match the conversation that’s happening,” Kelemen said. “While it’s growing, it’s still growing too slowly and definitely not in any way proportionate to the potential impact and the need of the actual population” that needs to be served.

    That said, Kelemen is optimistic funding will continue to increase. She’s also bullish on consolidation in the space and the potential for new innovations.

    “Because it is a hormonal change for a 10-, 15-, 20-year period, the needs of women will change,” she said. “There’s opportunity for multiple platforms to succeed.”

    View original article here

    Share. Facebook Twitter LinkedIn Email Reddit
    Previous ArticleAnanda balasana: 8 benefits and how to do happy baby pose
    Next Article United Airlines Flight Missing an External Panel Lands Safely

    Related Posts

    How Often Do Bonds Beat Stocks?

    November 20, 2026
    Read More

    Sweden’s H100 Lines Up Bitcoin Trading Revenue for Share Buybacks – BitRss

    November 19, 2026
    Read More

    A Strange Year in the Stock Market

    November 18, 2026
    Read More
    Add A Comment

    Leave A Reply Cancel Reply

    Demo
    Top Posts

    Former FBI, CIA Head Has ‘Serious Concerns’ With Trump Cabinet Picks

    December 28, 2024435

    Emirates to operate next-gen A350 on the third daily service to Cape Town

    January 14, 2026256

    AAVE Price Prediction: Target $215-225 by Mid-January 2025 as Technical Indicators Signal Bullish Momentum

    December 15, 2025240

    Wall Street Slumps As Alphabet, Qualcomm And Other Tech Stocks Fall

    February 7, 2026212
    Don't Miss
    Lifestyle

    How Water Collects on Flat Streets Near the Harbor

    By Staff WriterNovember 20, 20268 Mins Read

    What this covers The Setting Why Flat Streets Hold Water Tides and Drains What It…

    Read More

    What it means for your traffic

    November 20, 2026

    How Often Do Bonds Beat Stocks?

    November 20, 2026

    Why Black Friday and Cyber Monday Are Bad Days to Impulse Buy Electronics

    November 20, 2026
    Stay In Touch
    • Facebook
    • Twitter
    Demo
    Find More
    Trending News
    • How Water Collects on Flat Streets Near the Harbor
    • What it means for your traffic
    • How Often Do Bonds Beat Stocks?
    • Why Black Friday and Cyber Monday Are Bad Days to Impulse Buy Electronics
    • You Don’t Need Cash to Buy a Competitor
    • Anthropic’s IPO could deliver $156 billion to charity
    • Sweden’s H100 Lines Up Bitcoin Trading Revenue for Share Buybacks – BitRss
    • Nurses Share The Worst Mistakes They’ve Ever Seen
    • How to track your brand’s visibility in AI search [2026]
    • Biz4Group LLC – Company Profile
    Other News
    • Business
    • Feel Good
    • Finance
    • Fitness
    • Health
    • Investment
    • Lifestyle
    • Marketing
    • Politics
    • Small Business
    • Technology
    • Top Stories
    • Travel
    About Us

    Small Business Minder brings together business and related news from around the world in one place. Follow us for all the business news you'll need.

    Facebook X (Twitter)
    Our Picks

    How Water Collects on Flat Streets Near the Harbor

    November 20, 2026

    What it means for your traffic

    November 20, 2026
    Most Popular

    Former FBI, CIA Head Has ‘Serious Concerns’ With Trump Cabinet Picks

    December 28, 2024435

    Emirates to operate next-gen A350 on the third daily service to Cape Town

    January 14, 2026256
    Categories
    © 2026 Small Business Minder
    • Home
    • Get In Touch

    Type above and press Enter to search. Press Esc to cancel.

    Ad Blocker Enabled!
    Ad Blocker Enabled!
    Our website is made possible by displaying online advertisements to our visitors. To get the most from our site, please disable your Ad Blocker.